NRG-BN002: Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients with Newly Diagnosed GBM.
Andrew E SloanKathryn WinterMark R GilbertKenneth D AldapeSerah ChoiPatrick Yung WenNicholas ButowskiFabio M IwamotoRaju R RavalAlfredo D VoloschinCarlos Kamiya-MatsuokaMinhee WonMinesh P MehtaPublished in: Neuro-oncology (2024)
IPI and NIVO are safe and tolerable with toxicities similar to those noted with other cancers when given in combination with adjuvant TMZ for newly diagnosed GBM. Combination IPI+NIVO is not substantially more toxic than single agents. These results support a subsequent efficacy trial to test the combination of ICIs in a phase II/III for patients with newly diagnosed GBM.